Rallybio Initiates Phase 2 Trial Of RLYB212 To Address HPA-1a Alloimmunization And FNAIT In Pregnant Women, With Screening Underway Across European Sites For Target Enrollment Of Eight Participants
Rallybio Initiates Phase 2 Trial Of RLYB212 To Address HPA-1a Alloimmunization And FNAIT In Pregnant Women, With Screening Underway Across European Sites For Target Enrollment Of Eight Participants
Rallybio開始對RLYB212進行第二階段臨床試驗，以解決孕婦中的HPA-1a同種免疫和FNAIT，現已在歐洲各地進行篩查，目標招募八名參與者。
Rallybio Initiates Phase 2 Trial Of RLYB212 To Address HPA-1a Alloimmunization And FNAIT In Pregnant Women, With Screening Underway Across European Sites For Target Enrollment Of Eight Participants
Rallybio開始對RLYB212進行第二階段臨床試驗，以解決孕婦中的HPA-1a同種免疫和FNAIT，現已在歐洲各地進行篩查，目標招募八名參與者。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。